Feb 11, 2026Longevity Gene Activation: SIRT1, AMPK, mTOR, and NRF2 — Compound-by-Compound Evidence MapFour gene networks — SIRT1 (longevity deacetylase), AMPK (energy sensor), mTOR (growth regulator), and NRF2 (antioxidant response) — are the primary longevity targets for supplement intervention. This article maps which compounds activate which genes, the quality of evidence, and where interactions become relevant.
Feb 11, 2026Pterostilbene vs Resveratrol: Bioavailability, Sirtuin Activation, and Evidence ComparisonPterostilbene is a methylated resveratrol analog with substantially better oral bioavailability. It activates SIRT1 and AMPK, lowers blood pressure in some trials, but has fewer published human studies than resveratrol. The trade-off between bioavailability and evidence depth is real.
Feb 5, 2026mTOR, AMPK, and SIRT1: Longevity Pathway Switches and How Supplements Modulate ThemThree interlocked pathways — mTOR (growth/anabolism), AMPK (energy sensing), and SIRT1 (NAD-dependent deacetylase) — function as master longevity regulators. Supplements like rapamycin, berberine, and NMN modulate them through distinct entry points. Understanding the pathway logic prevents counterproductive stacking.
Feb 4, 2026Resveratrol and SIRT1: Longevity Pathway Activation, Human Trial Disappointments, and ContextResveratrol activated enormous interest as a SIRT1 activator after early animal data. Human trials have been largely disappointing for longevity endpoints. Benefits in specific metabolic contexts (glucose tolerance, inflammation) are more supported. Understanding the gap between mechanism and human outcome is essential.